Ledipasvir + sofosbuvir for liver transplant recipients with recurrent hepatitis C: A systematic review and meta-analysis
Transplantation Proceedings | Sep 21, 2017
Liao HT, et al. - This is the first meta-analysis that investigates the effectiveness of ledipasvir + sofosbuvir in liver transplantation recipients with hepatitis C virus (HCV) recurrence. Observations reveal that ledipasvir (LDV) + sofosbuvir (SOF)-based treatment is highly effective and well tolerated in liver transplant (LT) recipients with HCV reinfection.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
